Biohaven Announces Record Date for Anticipated Spin-Off
/PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") today announced that it has set a record date of September 26, 2022 (the...
Source: prnewswire.com
Channel Activators News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Channel Activators. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Channel Activators Today - Breaking & Trending Today
Real-World Administrative Claims Analysis Demonstrates That Almost Half of Migraine Patients Discontinue Barbiturate Use After Initiation of Nurtec ODT
Results from this study demonstrate a robust and clinically meaningful reduction in barbiturate use after the initiation of Nurtec ODT, providing an...
Source: prnewswire.com
American Migraine Foundation Survey Shows Nearly All People with Migraine and Healthcare Professionals Believe Migraine and Mental Health Significantly Impact Each Other
/PRNewswire/ -- The American Migraine Foundation (AMF) and Biohaven Pharmaceuticals (NYSE: BHVN) today announced findings from a new survey about migraine and...
Source: prnewswire.com
Pfizer Inc.: Pfizer and Biohaven's VYDURA (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing authorization for VYDURA (rimegepant), a
Source: finanznachrichten.de
Biohaven Announces Expanded Patient Access to Nurtec® ODT (rimegepant), Achieving Best-in-Class Commercial Insurance Coverage and Label Update
/PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced two updates regarding Nurtec® ODT (rimegepant), the only FDA-approved...
Source: prnewswire.com